Repeat Prostate-specific Antigen Test Research Articles

Reporting of research data by GPs: a cautionary tale for primary care researchers

Given the importance of community-based research, there is a need to ensure the quality of data obtained from such studies. However, research has been considered a low priority for most GPs. To assess the quality of data reported by GPs in a large community-based study. Men were recruited as part of a population-based study on prostate-specific antigen (PSA) testing. Those with elevated initial PSA levels in the mid-1990s and no investigation in the intervening period were invited for repeat PSA testing. The GP of each included man was contacted and asked to report basic clinical information. Trained data extractors independently reviewed each man's GP medical notes and recorded data relating to prostate problems. Data provided by GPs were rematched with data extracted from medical notes. A total of 758 men with 379 GPs were included. In all, 366 (96.6%) GPs agreed to participate. Of 698 men suitable for follow-up, GP and note review data were available in 505 (72.3%) cases (287 GPs). Overall, 245 (85.4%) GPs provided completely accurate data. Male GPs, compared to female GPs, were found to have a higher level of inaccurate reporting (P = 0.008). We found that when GPs were asked to record basic clinical information, for the purposes of a primary care-based study, there was a significant level of inaccurate reporting. The results from our study confirm the importance of quality control in primary care research, especially in studies that involve GPs' reporting data.

Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study

ObjectiveTo examine whether a single repeat prostate-specific antigen (PSA) helps discriminate cancer from non–cancer-related PSA elevation. MethodsMen aged 50–70 yr (n=54,087) in a multicentre randomised controlled trial comparing treatments for localised prostate cancer were tested. A total of 4102 (7.6%) with an initial PSA in the range of 3–19.9ng/ml had repeat measurement (median interval: 50 d) followed by prostate biopsy. The decision to biopsy was based on the first PSA level. The outcome was the presence of prostate cancer on biopsy. ResultsMen with a 20% drop in PSA had a lower risk of cancer (odds ratio [OR]=0.43; 95% confidence interval [CI], 0.35–0.52; p<0.001) and high-grade cancer (OR=0.29; 95%CI, 0.19–0.44; p<0.001) compared to the rest of the cohort. The effect of percentage reduction was greater in men aged ≤60 yr than in those >60 yr. (OR for any cancer=1.6; 95%CI, 1.0–2.4; p=0.05; OR for high-grade cancer=2.9; 95%CI, 1.2–6.7; p=0.014). This equated to a risk reduction of high-grade cancer from 4% to 0.5%, 6% to 2%, and 15% to 2% in men ≤60 yr with an initial PSA of 3.0–3.99, 4.0–5.99, and ≥6ng/ml, respectively. No level of repeat PSA confidently predicted absence of cancer. ConclusionFollowing an initial PSA of 3.0–19.99ng/ml in men aged 50–70 yr, repeat PSA within 7 wk allows more accurate risk prediction that may assist in the decision-making as to whether or not to proceed with prostate biopsy.

PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER

No AccessJournal of UrologyCLINICAL UROLOGY: Case Reports1 Mar 2002PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER WILLIAM K. OH, MASSIMO LODA, PHILIP W. KANTOFF, and MILOS JANICEK WILLIAM K. OHWILLIAM K. OH More articles by this author , MASSIMO LODAMASSIMO LODA More articles by this author , PHILIP W. KANTOFFPHILIP W. KANTOFF More articles by this author , and MILOS JANICEKMILOS JANICEK More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65312-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER." The Journal of Urology, 167(3), p. 1392 References 1 : Mechanisms of the development of osteoblastic metastases. Cancer, suppl.1997; 80: 1581. Google Scholar 2 : Metastatic prostate carcinoma to the foot with magnetic resonance imaging and pathologic correlation. Foot Ankle Int1998; 19: 594. Google Scholar 3 : Metastatic tumors to the bones of the foot.. Cancer1976; 37: 1492. Google Scholar From the Lank Center for Genitourinary Oncology, Department of Adult Oncology and Radiology, Dana-Farber Cancer Institute and Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 167Issue 3March 2002Page: 1392 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsfootneoplasm metastasisprostatic cancerMetricsAuthor Information WILLIAM K. OH More articles by this author MASSIMO LODA More articles by this author PHILIP W. KANTOFF More articles by this author MILOS JANICEK More articles by this author Expand All Advertisement PDF downloadLoading ...